Provided by Tiger Fintech (Singapore) Pte. Ltd.

Akero Therapeutics

53.84
+0.18000.34%
Post-market: 53.890.0500+0.09%19:52 EDT
Volume:1.58M
Turnover:84.69M
Market Cap:4.31B
PE:-14.24
High:53.87
Open:53.67
Low:53.63
Close:53.66
52wk High:58.40
52wk Low:21.34
Shares:79.99M
Float Shares:67.77M
Volume Ratio:0.33
T/O Rate:2.33%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7801
EPS(LYR):-3.7544
ROE:-31.14%
ROA:-20.36%
PB:4.20
PE(LYR):-14.34

Loading ...

Akero Therapeutics CEO Andrew Cheng Reports Disposal of Common Shares

Reuters
·
Oct 15

TD Cowen Downgrades Akero Therapeutics to Hold From Buy, Adjusts Price Target to $58 From $76

MT Newswires Live
·
Oct 13

Why Biotech's Rally Can Last This Time -- Heard on the Street -- WSJ

Dow Jones
·
Oct 13

U.S. RESEARCH ROUNDUP-American Express, BlackRock, Domino's Pizza

Reuters
·
Oct 13

Hold Rating on Akero Therapeutics Amid NOVO Acquisition and Regulatory Uncertainties

TIPRANKS
·
Oct 11

Novo Nordisk's Akero Deal Makes Sense But Raises Questions -- Market Talk

Dow Jones
·
Oct 10

Post-Bell | Wall Street Closes Lower; Nvidia and Meta Gain 2%; AMD Drops 1%; Tilray Jumps 22%; Serve Robotics Surges 29%

Tiger Newspress
·
Oct 10

Akero Therapeutics Chief Scientific Officer Timothy Rolph Reports Disposal of Common Shares

Reuters
·
Oct 10

Analysts Conflicted on These Healthcare Names: Akero Therapeutics (AKRO) and HealthStream (HSTM)

TIPRANKS
·
Oct 10

Why Akero Therapeutics Stock Trounced the Market on Thursday

Motley Fool
·
Oct 10

Akero Therapeutics Inc - IF Deal Terminated Under Some Circumstances, Co to Pay $165 Mln Termination Fee to Novo Nordisk- SEC Filing

THOMSON REUTERS
·
Oct 10

Akero Therapeutics downgraded to Peer Perform from Outperform at Wolfe Research

TIPRANKS
·
Oct 10

Akero Therapeutics Cut to Hold From Buy by Jefferies

Dow Jones
·
Oct 10

Market Chatter: Novo Nordisk CEO Poised to Take Risks in Weight-Loss Rivalry

MT Newswires Live
·
Oct 09

Akero downgraded to Market Perform from Outperform at LifeSci Capital

TIPRANKS
·
Oct 09

Cautious Hold Rating on Akero Therapeutics Amid Novo Nordisk Acquisition and Regulatory Uncertainties

TIPRANKS
·
Oct 09

Cautious Hold Rating on Akero Therapeutics Amid Acquisition Interest and Uncertainties in Efruxifermin’s Clinical Trajectory

TIPRANKS
·
Oct 09

Akero Therapeutics Inc : Jefferies Cuts to Hold From Buy; Cuts Target Price to $56 From $75

THOMSON REUTERS
·
Oct 09

Canaccord Genuity Downgrades Akero Therapeutics to Hold From Buy

MT Newswires Live
·
Oct 09

Akero Therapeutics downgraded to Hold from Buy at Canaccord

TIPRANKS
·
Oct 09